

Enteric-coated capsule containing β -galactosidase-loaded polylactic acid nanocapsules: enzyme stability and milk lactose hydrolysis under simulated gastrointestinal conditions

Hongjun He^{1*}, Xueting Zhang¹ and Yan Sheng²

¹College of Life Sciences, Yantai University, Yantai 264005, PR China

²College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, PR China

Received 1 April 2014; accepted for publication 12 August 2014; first published online 29 September 2014

In order to protect peroral β -galactosidase from being degraded and hydrolyse milk lactose efficiently in the environments of gastrointestinal tract, a double-capsule delivery system composed of enteric-coated capsule and polylactic acid (PLA) nanocapsules (NCs) was developed for encapsulation of β -galactosidase. β -galactosidase-loaded PLA NCs in the size range of 100–200 nm were prepared by a modified $w_1/o/w_2$ technique. During the encapsulation process, dichloromethane/ethyl acetate (1:1, v/v) as the solvent composition, high-pressure homogenisation (150 bar, 3 min) as the second emulsification method and polyvinyl alcohol or Poloxamer 188 as a stabiliser in the inner phase could efficiently improve the activity retention of β -galactosidase (> 90%). Subsequently, the prepared NCs were freeze-dried and filled in a hydroxypropyl methylcellulose phthalate (HP55)-coated capsule. In vitro results revealed that the HP55-coated capsule remained intact in the simulated gastric fluid and efficiently protected the nested β -galactosidase from acidic denaturation. Under the simulated intestinal condition, the enteric coating dissolved rapidly and released the β -galactosidase-loaded PLA NCs, which exhibited greater stability against enzymatic degradation and higher hydrolysis ratio (~ 100%) towards milk lactose than the free β -galactosidase. These results suggest that this double-capsule delivery system represents promising candidate for efficient lactose hydrolysis in the gastrointestinal tract.

Keywords: Lactose hydrolysis, β -galactosidase, polymeric nanocapsules, enteric-coated capsule, simulated gastrointestinal conditions.

Lactose is the primary disaccharide in mammalian milk, and also in a broad range of dairy products and processed foods such as ice cream and confectionery. β -galactosidase (lactase) is located at the brush border of enterocytes, where it hydrolyses lactose into glucose and galactose (Gilat et al. 1972). The interest in lactose hydrolysis has been driven mainly by the fact that more than 70% of the world's population continuously loses the ability to produce lactase after weaning that may result in lactose intolerance (Harrington & Mayberry, 2008). Symptoms of lactose intolerance include flatulence, abdominal pain and diarrhoea or even muscle pain and loss of concentration (Casellas et al. 2009). Peroral microbial-derived lactase preparations, such as tablets and capsules, has proven successful in alleviating the gastrointestinal (GI) symptoms caused by lactose uptake (Ramirez et al. 1994; Montalto et al. 2005). However, the so far available preparations are only effective when administered

in large doses immediately with the lactose-containing food as they have to confront acidic denaturation and enzymatic degradation in the GI tract (Lin et al. 1993; Montalto et al. 2006). Thereupon, a desirable lactase preparation which could efficiently protect the enzyme in the GI tract is worthy of study.

Polymeric nanocapsules (NCs), mainly composed of poly(lactic acid) (PLA) or poly(lactide-co-glycolide) (PLGA), are biocompatible, biodegradable and semi-permeable, allowing small molecules to penetrate, but proteins/enzymes to cut off (Dziubla et al. 2008; Sheng et al. 2009a). Conceivably, encapsulation of lactase in the PLA/PLGA NCs permeable to lactose but impermeable to proteases could be effectively resistant to enzymatic degradation. Enteric coating is an effective technology for the specific intestinal release of cargo after oral administration, which is based on pH-sensitive polymers, including hydroxypropyl methylcellulose phthalate (HPMCP, HP55) (Cui et al. 2007), polymethacrylic acid (Sajeesh et al. 2010), and so on. Based on these aspects, our idea in here was to develop an enteric-coated capsule containing PLA NCs as a carrier for the oral

*For correspondence; e-mail: hemiles@163.com

delivery of lactase. The basic concept is that the enteric-coated capsule remains intact in the highly acidic environment of stomach, but dissolved rapidly to release lactase-loaded PLA NCs in the neutral or slightly basic environment of small intestine.

For this purpose, lactase-loaded PLA NCs were firstly prepared by water-in-oil-in-water ($w_1/o/w_2$) solvent diffusion/evaporation method. The enzyme from *Kluyveromyces* (*K.*) *lactis* was chosen, which exhibits optimum activity in the small intestine. Effects of preparation parameters on the enzyme activity were investigated. Thereafter, the prepared NCs were freeze-dried and their physicochemical characteristics were examined. Then, the freeze-dried NCs were filled in hard gelatin capsules and subsequently coated with pH-sensitive enteric polymer, HP55 (complex capsule). To verify their ability to protect the encapsulated lactase from acidic denaturation and enzymatic degradation in the GI tract, the enzyme stability of complex capsules in the simulated gastric and intestinal fluids was determined, respectively. Finally, *in vitro* milk lactose hydrolysis in the simulated intestinal fluid was examined.

Materials and methods

Materials

PLA (Mw 80k) was supplied by DaiGang Biotechnology (Jinan, China). Lactase from *K. lactis* (Lactozym[®]; ≥ 3000 U/ml) and *o*-nitrophenyl- β -D-galactopyranoside (ONPG) were bought from Sigma-Aldrich (Shanghai, China). HP55 was purchased from Ruitai Chemical Co., Ltd. (Tai'an, China). Polyvinylalcohol (PVA) (1750 ± 50 DP, 87–89% hydrolysed) and sucrose were supplied by Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Poloxamer 188 was obtained from Shenyang Pharmaceutical University (Shenyang, China). Hard gelatin capsule (size 9) was purchased from Torpac Inc. (NJ, USA). Millipore water (Bedford, USA) was used throughout the experiment. All other reagents and solvents were of analytic grade.

Preparation of lactase-loaded PLA NCs

Lactase-loaded PLA NCs were prepared by the $w_1/o/w_2$ solvent diffusion/evaporation method (Sheng et al. 2009b) with some modifications. Briefly, 0.5 ml diluted Lactozym[®] solution (≥ 600 U/ml) (w_1) was emulsified in 5 ml organic solvent (*o*) containing 10 mg PLA by ultrasonic (JYD-900, Zhixin Instrument Co., Ltd., China) for 15 s. Thereafter, the primary emulsion was poured into 50 ml 0.5% PVA aqueous solution (w_2) followed by two steps of re-emulsification to obtain the double emulsion. The double emulsion was subsequently diluted into 150 ml 0.5% PVA aqueous solution (w_2) and then vacuumed to completely remove the solvents. The NCs were collected by centrifugation (GL-21M, Shanghai Centrifuge Institutes Co., Ltd., China) at 20000 g for 30 min at 4 °C and washed three times with Millipore water before lyophilisation.

Preparation of freeze-dried NCs

The above-obtained NCs were freeze-dried. To prevent aggregation, mannitol with certain concentration was used as a cryoprotectant during the freeze-drying process. In brief, an aqueous NC suspension was mixed with an equal volume of aqueous cryoprotectant. This mixture was frozen in a refrigerator and then lyophilised using a freeze dryer (Boyikang instrument company, Beijing, China) to obtain the NCs in powder form.

Morphology and particle size of NCs

The morphology of freeze-dried NCs was observed under scanning electron microscopy (SEM) (JSM-6360LV/Falcon, Japan) and transmission electron microscopy (TEM) (JEM-2010, Japan). Particle size and polydispersity (PI) were determined at 25 °C by Dynamic Light Scattering (DLS) using Zetasizer[®] Nano ZS (Malvern Instrument Ltd., UK).

Lactase activity assay

Activities of free lactase and lactase encapsulated in PLA NCs were determined by a direct kinetic spectrophotometric assay based on the enzymatic cleavage of ONPG and the colorimetric detection of the resulting yellow *o*-nitrophenolate (ONP) (Wang et al. 2009) with some modifications. Sodium phosphate buffer (2 ml, 0.1 M, pH 6.8) containing 5 mM ONPG was heated to 37 °C for 10 min. Upon the addition of 0.5 ml lactase solution or NC dispersion, the mixture was incubated at 37 °C in a water bath for 15 min and the concentration of ONP was monitored versus time by measuring the absorbance at 420 nm using a UV-vis spectrophotometer (U-2001, Hitachi). One unit of enzyme activity was defined as 1 μ M ONP formed/min.

Preparation of HP55-coated capsules containing lactase-loaded PLA NCs

Hard gelatin capsules were filled with lactase-loaded PLA NCs as the manufacturer's instructions. The capsules were then immersed into HP55 solution (15% w/v) of dichloromethane (DCM) and acetone (4:1, v/v) followed by air drying at room temperature.

Enzyme stability under simulated gastric and intestinal conditions

HP55-coated capsules containing lactase-loaded PLA NCs were incubated in the simulated gastric fluid (SGF, United State Pharmacopoeia XXVI, pH 1.2, pepsin 0.32% w/v) and simulated intestinal fluid (SIF, United State Pharmacopoeia XXVI, pH 6.8, pancreatin 1% w/v), respectively, at a concentration of 1 mg/ml and shaken (37 °C, 100 rpm) using a constant-temperature shaker (Jinghong Laboratory Instrument Co. Ltd., China). For SGF test, at defined time intervals,

the capsules were taken, washed three times and then re-suspended in the SIF under the condition (37 °C, 100 rpm, 1 h) to dissolve the enteric coating. Subsequently, the released NCs were collected by centrifugation (20000 g, 10 min) to determine the encapsulated lactase activity. For SIF test, at defined time intervals, the released NCs were collected to determine the encapsulated lactase activity. The test sample was directly suspended in the SIF for 1 h and then collected to determine the encapsulated lactase activity, which was the initial 100% activity. Free lactase and lactase-loaded PLA NCs were used as control.

In vitro lactose hydrolysis

Lactose hydrolysis by lactase encapsulated in PLA NCs was determined according to Kwak et al. (2002) with some modifications. Briefly, the PLA NCs (10 mg) were suspended in the SIF (10 ml) and shaken (37 °C, 100 rpm). Then 2 ml milk containing 4.8% lactose was added. At defined interval of enzymatic lactose hydrolysis, 0.5 ml sample was taken and the reaction was stopped by adding 1 ml perchloric acid (1 M). After centrifugation (20000 g, 4 °C, 10 min), the supernatant was neutralised and then filtered for measuring the lactose content by high-performance liquid chromatograph. A standard curve was constructed by injecting lactose standards, which yielded a linear curve. The lactose content was quantitatively determined by comparing with the standard curve. Free lactase was used as control.

Statistical analysis

Results were expressed as mean \pm SD. All data were generated in three independent experiments. Statistical analysis was performed with one-way analysis of variance (ANOVA). Differences were considered to be significant at a level of $P < 0.05$.

Results and discussion

Preparation parameters affecting lactase activity

$w_1/o/w_2$ solvent diffusion/evaporation technique has been chosen as one of the most appropriate methods for the encapsulation of water-soluble proteins. During the encapsulation process, polymers, emulsifiers and other adjuvants used are all approved by U.S. Food and Drug Administration. Even when such a relatively mild method is applied, proteins are exposed to organic solvents and mechanic stress, which can lead to structural and/or chemical degradation of sensitive proteins (Li et al. 2000). Optimisation of preparation parameters and addition of enzyme stabilisers are usually thought of effective means for the retention of enzyme activity.

As we know, organic solvent may easily change the high-grade structure of proteins and eventually cause denaturation. DCM and ethyl acetate (EA) are the commonly used solvents in the $w_1/o/w_2$ technique. The effect of solvent composition on the activity of lactase encapsulated in

Table 1. Effect of stabilizer in the internal aqueous phase on the activity of lactase encapsulated in PLA NCs

| Stabiliser type | Activity retention of lactase (%) |
|-----------------|-----------------------------------|
| w/o | 79.29 \pm 3.11 ^a |
| PVA | 93.86 \pm 3.03 ^b |
| Poloxamer 188 | 90.68 \pm 2.64 ^b |
| Sucrose | 81.03 \pm 2.75 ^a |

All values indicate mean \pm SD for $n=3$ independent experiments

^{a,b}Means in the same column with different superscript letters differ significantly ($P < 0.05$)

PLA NCs was investigated. Compared with the pure solvent DCM, when binary solvent DCM/EA was adopted, the lactase activity was increased significantly ($P < 0.05$). The activity retention of lactase in the case of DCM, DCM/EA (2:1, v/v) and DCM/EA (1:1, v/v) was (43.16 \pm 4.07)%, (68.05 \pm 1.50)% and (79.29 \pm 3.11)%, respectively. With further increasing the ratio of EA/DCM, the NCs were hardly formed (data not shown). Compared with DCM, EA induced less loss of enzyme activity, which was similar to the results observed by Sturesson & Carlfors (2000). However, Gander et al. claimed that neither EA nor DCM had any detrimental effect on bovine serum albumin (Gander et al. 1995). Thus, we can speculate that different proteins/enzymes have different sensitivities to solvent exposures.

During the second-emulsification procedure to form the $w_1/o/w_2$, proteins/enzymes may be subjected to fierce stirring. Ultrasonic and high-pressure homogenisation are the most frequently used techniques for the emulsion formation. Our previous experiments have optimised that ultrasonic (80 W, 3 min) and high-pressure homogenisation (150 bar, 3 min) could obtain the comparable nanometer-sized capsules. Compared with ultrasonic (59.32 \pm 4.55)%, higher activity retention of lactase was achieved by high-pressure homogenisation (77.18 \pm 3.71)% ($P < 0.05$). It has been demonstrated that with the similar droplet diameters, lower energy density was produced by high-pressure homogenisation when compared with ultrasonic (Schultz et al. 2004), which may avoid the enzyme aggregation and instability.

The presence of additives in the internal aqueous phase was reported to be beneficial for reducing the breakdown of structural integrity and hence the loss of protein/enzyme activity during the preparation process (Li et al. 2000). As shown in Table 1, both PVA and Poloxamer 188 had a pronounced stabilising effect on the lactase, exhibiting the activity retention of (93.86 \pm 3.03)% and (90.68 \pm 2.64)%, respectively. Partially hydrolysed PVA, which is well-known for its desirable surface active property, could probably prevent enzyme adsorption onto the water/solvent interface. It was reported that poloxamer formed a micellar structure from which the hydrated water was excluded as the temperature was elevated, causing the micellar entanglement and gel formation (Schmolka, 1991). Therefore, lactase was supposed to be entrapped in this hydrated network and thus protected from the interaction with organic solvents. By




Fig. 1. SEM image of freeze-dried lactase-loaded PLA NCs (a) without mannitol; (b) with 0.5% mannitol; (c) with 2% mannitol; (d) TEM image of freeze-dried lactase-loaded PLA NCs.

contrast, sucrose did not exert any stabilising effect on the lactase. The disaccharide sucrose stabilises proteins against unfolding through the preferential hydration mechanism (Weert et al. 2000). It is plausible that sucrose is preferentially excluded from the water/solvent interface and thus unable to prevent emulsion-induced denaturation of lactase.

Characterisation of the PLA NCs

It is well-known that freeze-drying process could induce the irreversible aggregation and/or fusion of NCs by the stress of freezing and dehydration (Abdelwahed et al. 2006a). Cryoprotectants are usually added into the NC suspension before freezing to protect their structural integrity and bio-activity of proteins encapsulated (Abdelwahed et al. 2006b). In this study, the effect of mannitol as a cryoprotectant at varying concentrations was evaluated during the process of freeze-drying NCs. Physicochemical characteristics of the prepared PLA NCs before and after freeze-drying were investigated and compared in Figs. 1 & 2. Before freeze-drying, the PLA NCs had a mean particle size of (198 ± 5) nm with PI of 0.129. After freeze-drying, the NCs without the addition of mannitol resulted in the formation of NC aggregates (Fig. 1a). By contrast, spherical boundary could




Fig. 2. Influences of freeze-drying process with different concentrations of mannitol on the particle size and PI of lactase-loaded PLA NCs.

be observed in the presence of mannitol (Fig. 1b). With up to 2% mannitol, NCs were found to be embedded in a matrix (Fig. 1c) and could be readily resuspended in water. TEM images revealed that the NCs were relatively well mono-dispersed with a well-defined spherical shape (Fig. 1d).




Fig. 3. Activity variations of free lactase and lactase encapsulated in PLA NCs or complex capsules incubated in pepsin-containing artificial gastric juice at 37 °C as a function of time. Data represent mean \pm SD, $n = 3$.




Fig. 4. Activity variations of free lactase and lactase encapsulated in PLA NCs or complex capsules incubated in pancreatin-containing artificial intestinal juice at 37 °C as a function of time. Data represent mean \pm SD, $n = 3$.

The particle size and PI of NCs before and after freeze-drying in the presence of 2% mannitol were comparable (Fig. 2). It is generally accepted that mannitol forms hydrogen bonds with the test NCs in lieu of water molecules during freezing stage (Shi et al. 2012), which could prevent the aggregation of NCs and protect them against the mechanical stress of ice crystals. Hence, the freeze-dried PLA NCs prepared in the presence of 2% mannitol were selected for further evaluations.

Enzyme stability in simulated gastric and intestinal fluids

The GI tract presents a unique microenvironment of enzymes and ionic strength, which impact both the chemical and colloidal stability of oral delivery systems (Gamboa & Leong, 2013). The stability of complex capsules in the GI tract was determined by measuring the remaining activity of encapsulated lactase. As shown in Fig. 3, the remaining activity of lactase in complex capsules achieved (73.46 \pm 3.28)% after 200 min incubation in the SGF, whereas the control free lactase and lactase-loaded PLA NCs lost their activities soon under the same condition ($P < 0.05$). It is well-known that the stomach contains pepsin and hydrochloric acid, which degrade proteins (Lain, 2009). PLA NCs impermeable to pepsin could protect the fragile lactase from enzymatic degradation but failed to prevent acidic denaturation since micromolecular hydrochloric acid could penetrate through the semi-permeable NCs. PLA NCs, further enveloped into the enteric-coated capsule, could withstand the harsh acidic environment due to the compact enteric coating, preventing the direct contact of lactase with hydrochloric acid molecules as well as pepsins.

Our preliminary experiments have demonstrated that the enteric coating could completely dissolve in the SIF within 1 h at 37 °C and 100 rpm. As shown in Fig. 4, the remaining




Fig. 5. Hydrolysis pattern of lactose by free lactase and lactase encapsulated in PLA NCs during incubation in pancreatin-containing artificial intestinal juice at 37 °C. Data represent mean \pm SD, $n = 3$.

activity of lactase in PLA NCs and complex capsules achieved (66.28 \pm 2.93)% and (80.47 \pm 2.63)%, respectively, after 6 h incubation in the SIF, whereas the control free lactase was almost completely degraded under the same condition ($P < 0.05$). The small intestine contains pancreatic juices like pancreatin, which breaks peptide bonds (Lain, 2009). Above results indicated that the complex capsules were stable when they stayed in the stomach and dissolved rapidly to release the PLA NCs after they went down to the small intestine. Thereafter, the released PLA NCs were impermeable to proteins/enzymes and thus protected the encapsulated lactase from action of pancreatin. From the data presented here it seems reasonable to conclude that lactase nested in the complex capsules could be better

protected from acidic denaturation and enzymatic degradation in the GI tract and hence the efficacy of lactase could be further enhanced.

Lactose hydrolysis

The time-dependent enzymatic lactose hydrolysis in the SIF was shown in Fig. 5. The lactose hydrolysis by free lactase showed a biphasic profile, an initial rapid hydrolysis followed by a slow and nearly static state, indicating that the free lactase was enzymatically degraded and lost its activity soon. By comparison, the lactose hydrolysis by lactase-loaded PLA NCs had an obvious retardation during the initial minutes followed by a sustained and progressive process, suggesting that lactase could diffuse through the PLA NCs and consequently be hydrolysed by the encapsulated lactase. Notably, nearly 100% of lactose in milk was hydrolysed by lactase-loaded PLA NCs, whereas free lactase only hydrolysed (61.7±1.8)% of milk lactose after 180 min incubation. The results suggested that this lactase preparation could exert excellent hydrolytic activity on milk lactose and thus has the potential of efficiently alleviating the symptoms associated with lactose intolerance. The next step was to investigate their in vivo enzymatic lactose hydrolysis.

HP55-coated capsule containing lactase-loaded PLA NCs was prepared in the present study. The obtained NCs were homogeneously sized (100–200 nm) and high activity retention of lactase was achieved by optimising the preparation parameters. The HP55-coated capsule prevented the nested lactase from contacting the highly acidic gastric medium, thereby against rapid acidic denaturation. Lactase encapsulated in the PLA NCs was well protected from enzymatic degradation and exert high hydrolytic activity on the permeable lactose under the simulated intestinal condition. Based on the above results, the double-capsule delivery system developed in this study might have potential for efficient lactose hydrolysis in the GI tract as well as oral delivery of other proteins with high bioavailability.

The authors wish to express their gratitude to the financial supports from National Natural Science Foundation of China (No. 31300789) and Natural Science Foundation of Shandong Province (No. ZR2013CQ016).

References

Abdelwahed W, Degobert G, Stainmesse S & Fessi H 2006a Freeze-drying of nanoparticles: formulation, process and storage considerations. *Advanced Drug Delivery Reviews* **58** 1688–1713

Abdelwahed W, Degobert G & Fessi H 2006b A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. *International Journal of Pharmaceutics* **309** 178–188

Casellas F, Varela E, Aparici A, Casaus M & Rodriguez P 2009 Development, validation, and applicability of a symptoms questionnaire for lactose malabsorption screening. *Digestive Diseases and Sciences* **54** 1059–1065

Cui FD, Tao AJ, Cun DM, Zhang LQ & Shi K 2007 Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. *Journal of Pharmaceutical Sciences* **96** 421–427

Dziubla TD, Shuvaev VV, Hong NK, Hawkins BJ, Madesh M, Takano H, Simone E, Nakada MT, Fisher A, Albelda SM & Muzykantor VR 2008 Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. *Biomaterials* **29** 215–227

Gamboa JM & Leong KW 2013 In vitro and in vivo models for the study of oral delivery of nanoparticles. *Advanced Drug Delivery Reviews* **65** 800–810

Gander B, Wehrli E, Alder R & Merkle HP 1995 Quality improvement of spray-dried, protein-loaded D,L-PLA microspheres by appropriate polymer-solvent selection. *Journal of Microencapsulation* **12** 83–97

Gilat T, Russo S, Gelman-Malachi E & Aldor TA 1972 Lactase in man: a nonadaptable enzyme. *Gastroenterology* **62** 1125–1127

Harrington LK & Mayberry JF 2008 A re-appraisal of lactose intolerance. *International Journal of Clinical Practice* **62** 1541–1546

Kwak HS, Kwon SH, Lee JB & Ahn J 2002 In vitro stability of beta-galactosidase microcapsules. *Asian-Australasian Journal of Animal Sciences* **15** 1808–1812

Lain C 2009 The mouth, stomach and intestines. *Anaesthesia and Intensive Care* **10** 336–338

Li XH, Zhang YH, Yan RH, Jia WX, Yuan ML, Deng XM & Huang ZT 2000 Influence of process parameters on the protein stability encapsulated in poly-DL-lactide-poly(ethylene glycol) microspheres. *Journal of Controlled Release* **68** 41–52

Lin M-Y, Dipalma JA, Martini MC, Gross CJ, Harlander SK & Savaiano DA 1993 Comparative effects of exogenous lactase (beta-galactosidase) preparations on in vivo lactose digestion. *Digestive Diseases and Sciences* **38** 2022–2027

Montalto M, Nucera G, Santoro L, Curigliano V, Vastola M, Covino M, Cuoco L, Manna R, Gasbarrini A & Gasbarrini G 2005 Effect of exogenous beta-galactosidase in patients with lactose malabsorption and intolerance: a crossover double-blind placebo-controlled study. *European Journal of Clinical Nutrition* **59** 489–493

Montalto M, Curigliano V, Santoro L, Vastola M, Cammarota G & Manna R 2006 Management and treatment of lactose malabsorption. *World Journal of Gastroenterology* **12** 187–191

Ramirez FC, Lee K & Graham DY 1994 All lactase preparations are not the same: results of a prospective, randomized, placebo-controlled trial. *American Journal of Gastroenterology* **89** 566–570

Sajeesh S, Vauthier C, Gueutin C, Ponchel G & Sharma CP 2010 Thiol functionalized polymethacrylic acid-based hydrogel microparticles. *Acta Biomaterials* **6** 3072–3080

Schmolka IR 1991 A comparison of block copolymer surfactant gels. *Journal of American Oil Chemists' Society* **68** 206–209

Schultz S, Wagner G, Urban K & Ulrich J 2004 High-pressure homogenization as a process for emulsion formation. *Chemical Engineering & Technology* **27** 361–368

Sheng Y, Liu CS, Yuan Y, Zhang XL, Shan XQ & Xu F 2009a Porosity and semipermeability of hemoglobin-loaded polymeric nanoparticles as potential blood substitutes. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* **91B** 631–642

Sheng Y, Yuan Y, Liu CS, Tao XY, Shan XQ & Xu F 2009b In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. *Journal of Materials Science: Materials in Medicine* **20** 1881–1891

Shi AM, Wang LJ, Li D & Adhikari B 2012 The effect of annealing and cryoprotectants on the properties of vacuum-freeze dried starch nanoparticles. *Carbohydrate Polymers* **88** 1334–1341

Sturesson C & Carlfors J 2000 Incorporation of protein in PLG-microspheres with retention of bioactivity. *Journal of Controlled Release* **67** 171–178

Wang H, Luo HY, Bai YG, Wang Y, Yang PL, Shi PJ, Zhang W, Fan YL & Yao B 2009 An acidophilic beta-galactosidase from *bispora* sp. MEY-1 with high lactose hydrolytic activity under simulated gastric conditions. *Journal of Agricultural and Food Chemistry* **57** 5535–5541

Weert M, Hoehstetter J, Hennink WE & Crommelin DJA 2000 The effect of a water/organic solvent interface on the structural stability of lysozyme. *Journal of Controlled Release* **68** 351–359